EP0280710A4 - Adn de codage de la proteine t4 de la surface des cellules t et utilisation de fragments de t4 pour le traitement du sida. - Google Patents

Adn de codage de la proteine t4 de la surface des cellules t et utilisation de fragments de t4 pour le traitement du sida.

Info

Publication number
EP0280710A4
EP0280710A4 EP19870905848 EP87905848A EP0280710A4 EP 0280710 A4 EP0280710 A4 EP 0280710A4 EP 19870905848 EP19870905848 EP 19870905848 EP 87905848 A EP87905848 A EP 87905848A EP 0280710 A4 EP0280710 A4 EP 0280710A4
Authority
EP
European Patent Office
Prior art keywords
amino acid
glycoprotein
immunodeficiency virus
human immunodeficiency
acid sequences
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP19870905848
Other languages
German (de)
English (en)
Other versions
EP0280710A1 (fr
EP0280710B1 (fr
Inventor
Paul J Maddon
Dan R Littman
Leonard Chess
Richard Axel
Robin Weiss
J Steven Mcdougal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Columbia University in the City of New York
Original Assignee
Columbia University in the City of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Columbia University in the City of New York filed Critical Columbia University in the City of New York
Publication of EP0280710A1 publication Critical patent/EP0280710A1/fr
Publication of EP0280710A4 publication Critical patent/EP0280710A4/fr
Application granted granted Critical
Publication of EP0280710B1 publication Critical patent/EP0280710B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/702—Specific hybridization probes for retroviruses
    • C12Q1/703—Viruses associated with AIDS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • AIDS & HIV (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EP87905848A 1986-08-21 1987-08-20 Adn de codage de la proteine t4 de la surface des cellules t et utilisation de fragments de t4 pour le traitement du sida Expired - Lifetime EP0280710B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US89858786A 1986-08-21 1986-08-21
US898587 1986-08-21
PCT/US1987/002050 WO1988001304A1 (fr) 1986-08-21 1987-08-20 Adn de codage de la proteine t4 de la surface des cellules t et utilisation de fragments de t4 pour le traitement du sida

Publications (3)

Publication Number Publication Date
EP0280710A1 EP0280710A1 (fr) 1988-09-07
EP0280710A4 true EP0280710A4 (fr) 1989-03-14
EP0280710B1 EP0280710B1 (fr) 1996-03-20

Family

ID=25409679

Family Applications (1)

Application Number Title Priority Date Filing Date
EP87905848A Expired - Lifetime EP0280710B1 (fr) 1986-08-21 1987-08-20 Adn de codage de la proteine t4 de la surface des cellules t et utilisation de fragments de t4 pour le traitement du sida

Country Status (9)

Country Link
US (2) US5871913A (fr)
EP (1) EP0280710B1 (fr)
JP (1) JP3134874B2 (fr)
AT (1) ATE135747T1 (fr)
AU (1) AU616639B2 (fr)
CA (1) CA1340627C (fr)
DE (1) DE3751751T2 (fr)
DK (1) DK175520B1 (fr)
WO (1) WO1988001304A1 (fr)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5292636A (en) * 1986-03-31 1994-03-08 T Cell Diagnostics, Inc. Therapeutic and diagnostic methods using soluble T cell surface molecules
US6673896B1 (en) 1986-08-21 2004-01-06 The Trustees Of Columbia University In The City Of New York Derivatives of soluble T-4
JP3134874B2 (ja) 1986-08-21 2001-02-13 ザ・トラステイーズ・オブ・コロンビア・ユニヴアーシテイ・イン・ザ・シテイ・オブ・ニユー・ヨーク Ｔ細胞表面タンパク質ｔ４をコードするｄｎａ並びにｔ４フラグメントのａｉｄｓ治療への使用
US5958678A (en) * 1986-08-21 1999-09-28 The Trustees Of Columbia University In The City Of New York DNA encoding the T cell surface protein T4 and use of fragments of T4 in the treatment of AIDS
US5110906A (en) * 1986-08-21 1992-05-05 The Trustees Of Columbia University In The City Of New York Derivatives of soluble T-4
AU609447B2 (en) * 1987-02-19 1991-05-02 Nissin Shokuhin Kabushiki Kaisha Methods and materials for hiv detection and therapy
US5217895A (en) * 1987-02-19 1993-06-08 Nissin Shokuhin Kabushiki Kaisha Monoclonal anti-idiotypic antibodies specific for anti-T4 antibodies and cross-reactive with HIV
US5169752A (en) * 1987-02-19 1992-12-08 Nissin Shokuhin Kabushiki Kaisha Methods and materials for HIV detection
US5140105A (en) * 1987-02-19 1992-08-18 Nissin Shokuhin Kabushiki Kaisha Methods and materials for HIV detection
US5180660A (en) * 1987-02-19 1993-01-19 Nissin Shokuhin Kabushiki Kaisha Methods and materials for HIV detection
EP0344211A4 (fr) * 1987-02-20 1990-03-12 Imclone Systems Inc Anticorps monoclonaux dans des compositions de vaccins.
WO1989001940A1 (fr) * 1987-09-04 1989-03-09 Biogen, Inc. Sequences d'adn, molecules d'adn recombinant et procedes de production de proteines t4 solubles
IL83687A (en) * 1987-08-30 1995-03-30 Yeda Res & Dev Pharmaceutical compositions comprising molecular decays and their use in the manufacture of said compositions
US6710169B2 (en) 1987-10-02 2004-03-23 Genentech, Inc. Adheson variants
AU618969B2 (en) * 1987-10-02 1992-01-16 Genentech Inc. Adheson variants
ZA887365B (en) * 1987-10-02 1990-05-30 Genentech Inc Adheson variants
US5336603A (en) * 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
PT88641B (pt) * 1987-10-02 1993-04-30 Genentech Inc Metodo para a preparacao de uma variante de adesao
IL87902A0 (en) * 1987-10-08 1989-03-31 Dana Farber Cancer Inst Inc Soluble human cd4 fragments and applications thereof
PT88783B (pt) * 1987-10-23 1993-01-29 Smithkline Beckman Corp Processo de purificacao de proteina t4 soluvel e de producao da mesma
US6004781A (en) * 1988-01-22 1999-12-21 The General Hospital Corporation Nucleic acid encoding Ig-CD4 fusion proteins
AU3006789A (en) * 1988-02-24 1989-08-24 Smithkline Beckman Corporation Expression of hiv binding proteins
EP0346091A3 (fr) * 1988-06-10 1990-09-12 Dana Farber Cancer Institute Procédé de diagnostic pour anticorps naturels contre cd4
EP0378643A4 (en) * 1988-06-10 1990-12-27 Biogen, Inc. Combinations of soluble t4 proteins and anti-retroviral agents and methods for treating or preventing aids, arc and hiv infection
WO1990001870A1 (fr) * 1988-08-22 1990-03-08 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce Vecteurs de retrovirus exprimant des cd4 solubles: therapie genique pour le sida
DE3828582A1 (de) * 1988-08-23 1990-03-01 Max Planck Gesellschaft Monoklonaler antikoerper zur inhibierung der infektion von zellen durch hiv-viren
CA2000989A1 (fr) * 1988-10-18 1990-04-18 Harry M. Meade Conjugats de proteines t4 solubles et de toxines et methode de traitement pour la prevention de l'infection par les virus du sida, arc & hiv
JPH04502011A (ja) * 1988-11-23 1992-04-09 ジェネンテク，インコーポレイテッド ポリペプチド誘導体
EP0454767A1 (fr) * 1989-01-18 1991-11-06 The President And Fellows Of Harvard College Compositions et procedes de traitement ou de prophylaxie du sida, de complexes apparentes au sida et d'infections par vih
AU5437190A (en) * 1989-04-05 1990-11-05 Upjohn Company, The Soluble cd4 produced in (e. coli)
EP0408372A1 (fr) * 1989-07-13 1991-01-16 Smithkline Beecham Corporation Thérapie antivirale
JPH0353894A (ja) * 1989-07-21 1991-03-07 Calpis Food Ind Co Ltd:The 抗ヒトｃｄ４ペプチドに対するモノクローナル抗体
JPH05500611A (ja) * 1989-08-23 1993-02-12 ザ・ジェネラル・ホスピタル・コーポレーション 非ヒト霊長類ｃｄ４ポリペプチド、グリコシル化可能なヒトｃｄ４分子、その断片、その融合タンパク質、その遺伝子配列および使用
EP0432693A1 (fr) * 1989-12-11 1991-06-19 Sumitomo Chemical Company, Limited Liposomes cytotoxiques à des cellules infectées par des virus
JPH03254693A (ja) * 1990-03-06 1991-11-13 Calpis Food Ind Co Ltd:The 抗イデオタイプ抗体作製用抗原、抗イデオタイプ抗体、及びその製法
AU1438592A (en) * 1991-02-08 1992-09-07 Progenics Pharmaceuticals, Inc. Cd4-gamma1 and cd4-igg1 chimeras
US7070991B2 (en) 1991-02-08 2006-07-04 Progenics Pharmaceuticals, Inc. Cells expressing a CD4-IgG2 chimeric heterotetramer
CA2080226C (fr) 1991-02-08 2004-05-04 Gary A. Beaudry Chimeres cd4-gamma2 et cd4-igg2
US5789152A (en) * 1991-04-30 1998-08-04 Basil T. Hone Composition and method for detecting HIV with baculovirus derived vesicles
AU3662293A (en) * 1992-02-10 1993-09-03 Progenics Pharmaceuticals, Inc. A method of using cd4-containing molecules to substantially reduce the risk of occupational hiv transmission
EP0664710A4 (fr) 1992-08-07 1998-09-30 Progenics Pharm Inc IMMUNOCONJUGUES CD4-GAMMA2 ET CD4-IgG2 A FRACTION CONJUGUEE NON PEPTIDYLE, ET LEURS UTILISATIONS.
US5817767A (en) * 1993-02-24 1998-10-06 Progenics Pharmaceuticals, Inc. Synergistic composition of CD4-based protein and anti-HIV-1 antibody, and methods of using same
JPH11507352A (ja) 1995-06-07 1999-06-29 ジンタ・インコーポレイテッド 新規カルバメート基本カチオン性脂質
US6342586B1 (en) 1996-06-10 2002-01-29 Progenics Pharmaceuticals, Inc. Non-peptidyl moiety-conjugated CD4-gamma2 and CD4-IgG2 immunoconjugates and uses thereof
EP0900841A1 (fr) * 1997-06-18 1999-03-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Variantes d'épissure de LAG-3
US7311920B1 (en) 1999-10-08 2007-12-25 University Of Maryland Biotechnology Institute Virus coat protein/receptor chimeras and methods of use
US6908612B2 (en) 1999-10-08 2005-06-21 University Of Maryland Biotechnology Institute Virus coat protein/receptor chimeras and methods of use
US20030157063A1 (en) * 2001-12-21 2003-08-21 Jean-Louis Touraine Gene therapy using anti-gp41 antibody and CD4 immunoadhesin
KR20050099536A (ko) * 2003-02-06 2005-10-13 트리펩 아베 글리코실화된 특이성 교환체
JP4038679B2 (ja) * 2003-05-13 2008-01-30 住友電気工業株式会社 半導体レーザーバーの固定用治具
WO2006098724A1 (fr) * 2005-03-11 2006-09-21 The Regents Of The University Of California Procedes destines au traitement du vih en inhibant la modulation decroissante du cd4
US20130158339A1 (en) 2011-12-16 2013-06-20 General Electric Company System and Method of Infant Care Control and Workflow
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US621054A (en) * 1899-03-14 Horatio frederick forrest
JPS57144983A (en) 1981-02-27 1982-09-07 Otsuka Pharmaceut Factory Inc Preparation of physiologically active substance
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4520113A (en) * 1984-04-23 1985-05-28 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Serological detection of antibodies to HTLV-III in sera of patients with AIDS and pre-AIDS conditions
US4663436A (en) * 1984-04-24 1987-05-05 Scripps Clinic And Research Foundation Leukemia-associated virus immunogen, vaccine and assay
US4761371A (en) 1985-02-12 1988-08-02 Genentech, Inc. Insulin receptor
US4629783A (en) * 1985-04-29 1986-12-16 Genetic Systems Corporation Synthetic antigen for the detection of AIDS-related disease
US5110906A (en) 1986-08-21 1992-05-05 The Trustees Of Columbia University In The City Of New York Derivatives of soluble T-4
US5126433A (en) 1986-08-21 1992-06-30 The Trustees Of Columbia University In The City Of New York Soluble forms of the t cell surface protein cd4
JP3134874B2 (ja) 1986-08-21 2001-02-13 ザ・トラステイーズ・オブ・コロンビア・ユニヴアーシテイ・イン・ザ・シテイ・オブ・ニユー・ヨーク Ｔ細胞表面タンパク質ｔ４をコードするｄｎａ並びにｔ４フラグメントのａｉｄｓ治療への使用
WO1989001940A1 (fr) 1987-09-04 1989-03-09 Biogen, Inc. Sequences d'adn, molecules d'adn recombinant et procedes de production de proteines t4 solubles
PT88783B (pt) * 1987-10-23 1993-01-29 Smithkline Beckman Corp Processo de purificacao de proteina t4 soluvel e de producao da mesma

Also Published As

Publication number Publication date
US6570000B1 (en) 2003-05-27
DK175520B1 (da) 2004-11-22
EP0280710A1 (fr) 1988-09-07
WO1988001304A1 (fr) 1988-02-25
JP3134874B2 (ja) 2001-02-13
DE3751751D1 (de) 1996-04-25
CA1340627C (fr) 1999-07-06
AU7879287A (en) 1988-03-08
DE3751751T2 (de) 1996-10-17
DK217288D0 (da) 1988-04-21
US5871913A (en) 1999-02-16
JPH01500879A (ja) 1989-03-30
DK217288A (da) 1988-06-16
ATE135747T1 (de) 1996-04-15
EP0280710B1 (fr) 1996-03-20
AU616639B2 (en) 1991-11-07

Similar Documents

Publication Publication Date Title
DK217288A (da) Dna, der indkoder t-celleoverfladeproteinet t4, og anvendelse af t4-fragmenter ved behandling af aids
DE3588254D1 (de) Gag-Antigen und dessen Verwendung zum Nachweis von LAV-Infektion, sowie in immunogenen Zusammensetzungen
ES2013346A6 (es) Metodos para producir secuencias y moleculas de adn recombinante, asi como proteinas t4 solubles.
GR3023717T3 (en) Process for recovering native domains of viral membrane proteins, their use, in particular as vaccine against hiv.
FI113969B (fi) Menetelmä CD40:n liukoisen ligandin valmistamiseksi, sitä koodaava nukleiinihappo ja sen käyttö
IL91007A0 (en) Synthetic vaccine against aids virus
RU2005129271A (ru) Способ применения композиций, содержащих белки терлового шока или альфа-2-макроглобулин, для лечения рака и инфекционных болезней
SE8703225L (sv) Monoklonala antikroppar och peptider anvendbara vid behandling och diagnostisering av hiv-infektioner
DK0495896T3 (da) Vaccine til beskyttelse mod HIV-virusinfektioner, fremgangsmåde til fremstilling heraf og anvendelse heraf som diagnostisk middel og immunterapeutisk middel
HUT71847A (en) Dna molecules encoding aminopeptidase enzymes, vectors and transgenic cells containing dna molecules, immunogenic polypeptides encoding by dna molecules, vaccines against helminth infections containing these peptides and process for the preparation ...
ATE179614T1 (de) Herpes simplex virus vp16 impfstoffe
GB2324093A (en) Helicobacter pylori bacterioferritin
EP0306219A3 (fr) Protéines et peptides du HIV pour le diagnostic, la prophylaxie et la thérapie du SIDA
DE68925660D1 (de) Peptidfragmente von HIV
IE870507L (en) Bovine virus diarrhea and hog cholera vaccines
WO2002022687A3 (fr) Proteines de fusion chimiokine virale-antigene tumoral
WO2000012122A3 (fr) Fragments de l'acide hyaluronique de faible poids moleculaire pour la preparation de vaccins
BE1000167A4 (fr) Antigene du virus de l'hepatite b et procede pour sa production.
HU906421D0 (en) Process for testing analogous peptides of hiv
WO2003025002A3 (fr) Methode et compositions a base de proteines de fusion a antigene-defensine et de proteines de fusion a antigene-chimiokine utilisees comme vaccins contre les tumeurs et les infections virales
EP0218431A3 (en) Novel polypeptides, dnas that code for the same and method of preparing said polypeptides and dnas
NO20005321L (no) Vertskodet protein uttrykt i Mareks sykdoms (MDV) infiserte celler og antistoffer til dette
AU5125001A (en) Neutralizing immunogenic hev polypeptides
DE3856592D1 (de) Adhäsionsvarianten
RU2007148891A (ru) Иммунизация против chlamydia trachomatis

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

17P Request for examination filed

Effective date: 19880816

A4 Supplementary search report drawn up and despatched

Effective date: 19890314

EL Fr: translation of claims filed
TCNL Nl: translation of patent claims filed
ITCL It: translation for ep claims filed

Representative=s name: FUMERO BREVETTI S.N.C.

TCAT At: translation of patent claims filed
DET De: translation of patent claims
17Q First examination report despatched

Effective date: 19911108

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

REF Corresponds to:

Ref document number: 135747

Country of ref document: AT

Date of ref document: 19960415

Kind code of ref document: T

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: SCHMAUDER & WANN PATENTANWALTSBUERO, INHABER KLAUS

REF Corresponds to:

Ref document number: 3751751

Country of ref document: DE

Date of ref document: 19960425

ITF It: translation for a ep patent filed
ET Fr: translation filed
PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
REG Reference to a national code

Ref country code: GB

Ref legal event code: IF02

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20060705

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20060710

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20060713

Year of fee payment: 20

Ref country code: NL

Payment date: 20060713

Year of fee payment: 20

Ref country code: CH

Payment date: 20060713

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20060714

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20060801

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20060803

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20060831

Year of fee payment: 20

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

NLV7 Nl: ceased due to reaching the maximum lifetime of a patent

Effective date: 20070820

EUG Se: european patent has lapsed
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20070819

BE20 Be: patent expired

Owner name: THE *TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY O

Effective date: 20070820

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20070820

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20060720

Year of fee payment: 20